Algernon’s COVID-19 Response

Algernon's COVID-19 Response

Algernon has been aggressively engaged in advancing NP-120 (Ifenprodil) as a potential new therapeutic for COVID-19 patients:

March 13, 2020
Algernon Filed a pre-IND (Investigational New Drug) meeting request with the U.S. FDA for the treatment and prevention of ALI and acute respiratory distress syndrome (ARDS) associated with COVID-19 infection.

March 13, 2020
Algernon Contacts Gates Foundation Regarding Funding for the development of New COVID-19 Treatments.

March 19, 2020
Algernon announces support of a physician initiated planned Phase 2 trial of Ifenprodil for COVID-19 in South Korea.

March 20, 2020
Algernon appoints award winning Novotech as the contract research organization (“CRO”) for a planned physician-initiated study of Ifenprodil for COVID-19 patients in South Korea.

March 20, 2020
Algernon retains Novotech to conduct a feasibility study in Australia for a phase 2 sponsor initiated Ifenprodil COVID-19 trial. Novotech has already identified 3 physicians who have indicated their interest to participate.

March 23, 2020
Algernon appoints U.S. Based Cascade Chemistry to support its quickly evolving clinical program for ALI, its urgent clinical focus on COVID-19 as well as its idiopathic pulmonary fibrosis (IPF) and chronic cough clinical program.

March 30, 2020
Algernon announces that it has submitted for ethics approval in Australia for its planned Phase 2 study of its re-purposed drug NP-120 (Ifenprodil) for idiopathic pulmonary fibrosis (IPF) and chronic cough.

Share via
Copy link
Powered by Social Snap